Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.32 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292935 | 0.82 | PDK2 (0.45) | PDK2HSD17B10RARBRARGRXRA | |
| SCHEMBL6810766 | 0.77 | RARA (0.38) | PDK2RARBRARGRXRARARA | |
| SCHEMBL8433747 | 0.77 | RARA (0.50) | PDK2RARBRARGRARA | |
| SCHEMBL6810772 | 0.77 | RARA (0.49) | PDK2ALDH1A1RARBRARGRXRA | |
| SCHEMBL6810768 | 0.77 | RARA (0.49) | PDK2ALDH1A1RARBRARGRXRA | |
| SCHEMBL8664382 | 0.76 | RARB (0.44) | PDK2RARBRARGRXRARARA | |
| SCHEMBL2317156 | 0.75 | SCN9A (0.34) | PKM | |
| SCHEMBL13613859 | 0.74 | CYP26A1 (0.34) | PDK2RARBRARGRARA | |
| SCHEMBL24362710 | 0.73 | ALDH1A1 (0.34) | ALDH1A1HPGDTSHRHSD17B10EPAS1 | |
| SCHEMBL29599432 | 0.73 | ALDH1A1 (0.34) | ALDH1A1HPGDTSHRHSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | PDK2 1684/4885ALDH1A1 3081/4885HPGD 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.